These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 25380423)

  • 1. Gilead's interferon-free HCV combo approved.
    Nat Biotechnol; 2014 Nov; 32(11):1070. PubMed ID: 25380423
    [No Abstract]   [Full Text] [Related]  

  • 2. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
    Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
    [No Abstract]   [Full Text] [Related]  

  • 3. Perioperative Ledipasvir-Sofosbuvir for HCV in Liver-Transplant Recipients.
    Levitsky J; Verna EC; O'Leary JG; Bzowej NH; Moonka DK; Hyland RH; Arterburn S; Dvory-Sobol H; Brainard DM; McHutchison JG; Terrault NA
    N Engl J Med; 2016 Nov; 375(21):2106-2108. PubMed ID: 27959735
    [No Abstract]   [Full Text] [Related]  

  • 4. Membranous nephropathy associated with hepatitis C virus infection treated with corticosteroids and Ledipasvir-Sofosbuvir: a case report and review of literature.
    Weng Q; Li X; Ren H; Xie J; Pan X; Xu J; Chen N
    Oncotarget; 2017 Mar; 8(13):22299-22303. PubMed ID: 28223549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interferon free recovery for almost all patients].
    Einecke D
    MMW Fortschr Med; 2015 Mar; 157(4):71. PubMed ID: 25743991
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapy with direct-acting antivirals for genotype 3 patients: interferon's last gasp?
    Esteban R; Buti M
    Gastroenterology; 2015 Nov; 149(6):1326-30. PubMed ID: 26416329
    [No Abstract]   [Full Text] [Related]  

  • 7. Ledipasvir-sofosbuvir for hepatitis C genotype 4 infection.
    Smith MA; Mohammad RA
    Lancet Infect Dis; 2015 Sep; 15(9):993-995. PubMed ID: 26187029
    [No Abstract]   [Full Text] [Related]  

  • 8. Curing the historically incurable: treatment success with ledipasvir/sofosbuvir for chronic hepatitis C virus in a heavily treatment-experienced individual.
    Johnson SW; Davis MM; Stever LM; Priest DH
    J Clin Pharm Ther; 2016 Dec; 41(6):727-729. PubMed ID: 27670742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct antiviral agents for treatment-naïve patients with genotype 1 hepatitis C: A statistical model for comparing outcomes between real world and clinical trials.
    Messori A; Brunetto MR; De Luca A; Zignego AL
    Dig Liver Dis; 2015 Nov; 47(11):988-9. PubMed ID: 26205830
    [No Abstract]   [Full Text] [Related]  

  • 10. A model-based meta-analysis of sofosbuvir-based treatments in chronic hepatitis C patients.
    Pérez-Pitarch A; Guglieri-López B; Ferriols-Lisart R; Merino-Sanjuán M
    Int J Antimicrob Agents; 2016 Mar; 47(3):184-94. PubMed ID: 26915476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two Antiviral Drugs Approved For Adolescents With HCV.
    Aschenbrenner DS
    Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749879
    [No Abstract]   [Full Text] [Related]  

  • 12. Hepatitis C drug maker puts profit ahead of patients, US Senate report charges.
    McCarthy M
    BMJ; 2015 Dec; 351():h6573. PubMed ID: 26635239
    [No Abstract]   [Full Text] [Related]  

  • 13. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).
    Bourlière M; Bronowicki JP; de Ledinghen V; Hézode C; Zoulim F; Mathurin P; Tran A; Larrey DG; Ratziu V; Alric L; Hyland RH; Jiang D; Doehle B; Pang PS; Symonds WT; Subramanian GM; McHutchison JG; Marcellin P; Habersetzer F; Guyader D; Grangé JD; Loustaud-Ratti V; Serfaty L; Metivier S; Leroy V; Abergel A; Pol S
    Lancet Infect Dis; 2015 Apr; 15(4):397-404. PubMed ID: 25773757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C?
    Sofia MJ
    Antiviral Res; 2014 Jul; 107():119-24. PubMed ID: 24792751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ledipasvir + sofosbuvir (Harvoni). A therapeutic advance in genotype 1 hepatitis C virus infection, despite uncertainties.
    Prescrire Int; 2015 Dec; 24(166):285-9. PubMed ID: 26788571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute liver failure during hepatitis C treatment with sofosbuvir and ledipasvir.
    Debes JD; Ricci P
    Dig Liver Dis; 2015 Dec; 47(12):1091-2. PubMed ID: 26427585
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
    Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
    Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal interferon-free therapy in treatment-experienced chronic hepatitis C patients.
    Peter J; Nelson DR
    Liver Int; 2015 Jan; 35 Suppl 1():65-70. PubMed ID: 25529089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New combination heals still more patients in an even shorter period of time].
    Einecke D
    MMW Fortschr Med; 2016 Feb; 158(3):14. PubMed ID: 27119668
    [No Abstract]   [Full Text] [Related]  

  • 20. 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
    Korean Association for the Study of the Liver (KASL)
    Clin Mol Hepatol; 2018 Sep; 24(3):169-229. PubMed ID: 30092624
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.